0.4499 -0.00 (-0.02%)
After hours: 4:56PM EDT
|Bid||0.4300 x 1400|
|Ask||0.4500 x 1000|
|Day's Range||0.4211 - 0.4698|
|52 Week Range||0.4200 - 3.0990|
|Beta (3Y Monthly)||2.27|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you want to know who really controls Aileron Therapeutics, Inc. (NASDAQ:ALRN), then you'll have to look at the...
Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Every investor in Aileron Therapeutics, Inc. (NASDAQ:ALRN) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often Read More...
Aileron Therapeutics (ALRN) signs a clinical trial collaboration contract with Pfizer to study the combo of Aileron's ALRN-6924 and Pfizer's Ibrance for treating MDM2-amplified cancers. Stock rises.